Dr. Caroline Williams-Gray, a Clinical Research Professor at the University of Cambridge, brings extensive experience in neurodegenerative disease to the company. She currently serves as Chief Investigator for the Phase 2 DAPA-PD trial, which evaluates dapansutrile in patients with early-stage Parkinson’s. Her work focuses on the role of immune activation in disease progression, providing a scientific foundation for Olatec’s ongoing neurological research.
Olatec Therapeutics Expands Leadership to Bolster NLRP3 Research
Olatec Therapeutics has appointed Parkinson’s disease expert Caroline Williams-Gray to its Clinical Advisory Board and physician-innovator David Haase to its Board of Directors. These additions signal a strategic push to advance the clinical development of dapansutrile, an oral inhibitor targeting the NLRP3 inflammasome across multiple chronic inflammatory conditions.
Dr. David Haase, founder of the Tennessee-based MaxWell Clinic, joins both the Board of Directors and the Clinical Advisory Board. With over 25 years of experience in personalized systems medicine, Dr. Haase has been a vocal proponent of targeting the NLRP3 inflammasome to address the root causes of metabolic and cognitive decline. His appointment emphasizes the company’s focus on long-term disease modification rather than symptomatic management. Damaris B. Skouras, CEO of Olatec, noted that these appointments reflect the increasing medical consensus regarding the potential of NLRP3 inhibition in treating diverse disease populations.
Comments (0)
No comments yet. Be the first!